Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer

A. B. Schrock, C. Ouyang, J. Sandhu, E. Sokol, D. Jin, J. S. Ross, V. A. Miller, D. Lim, I. Amanam, J. Chao, D. Catenacci, M. Cho, F. Braiteh, S. J. Klempner, S. M. Ali, M. Fakih

    Research output: Contribution to journalArticle

    18 Citations (Scopus)

    Abstract

    Background: Microsatellite instability (MSI) is a biomarker for response to immune checkpoint inhibitors (ICPIs). PD-1 inhibitors in metastatic colorectal carcinoma (mCRC) with MSI-high (MSI-H) have demonstrated a high disease control rate and favorable progression-free survival (PFS); however, reported response rates to pembrolizumab and nivolumab are variable and often <50%, suggesting that additional predictive biomarkers are needed. Methods: Clinicopathologic data were collected from patients with MSI-H mCRC confirmed by hybrid capture-based next-generation sequencing (NGS) treated with PD-1/L1 inhibitors at five institutes. Tumor mutational burden (TMB) was determined on 0.8-1.1 Mb of sequenced DNA and reported as mutations/Mb. Potential biomarkers of response and time to progression were analyzed by univariate and multivariate analyses. Once TMB was confirmed as a predictive biomarker, a larger dataset of 18 140 unique CRC patients was analyzed to define the relevance of the identified TMB cut-point. Results: A total of 22 patients were treated with PD-1/L1 inhibitors including 19 with pembrolizumab monotherapy. Among tested variables, TMB showed the strongest association with objective response (OR; P < 0.001) and PFS, by univariate (P < 0.001) and multivariate analysis (P < 0.01). Using log-rank statistics, the optimal predictive cut-point for TMB was estimated between 37 and 41 mutations/Mb. All 13 TMBhigh cases responded, while 6/9 TMBlow cases had progressive disease. The median PFS for TMBhigh has not been reached (median follow-up >18 months) while the median PFS for TMBlow was 2 months. A TMB of 37.4 mutations/Mb in a large MSI-H mCRC population (821/18, 140 cases; 4.5%) evaluated by NGS corresponded to the 35th percentile cut-point. Conclusions: TMB appears to be an important independent biomarker within MSI-H mCRC to stratify patients for likelihood of response to ICPIs. If validated in prospective studies, TMB may play an important role in guiding the sequencing and/or combinations of ICPIs in MSI-H mCRC.

    Original languageEnglish (US)
    Article numbermdz134
    Pages (from-to)1096-1103
    Number of pages8
    JournalAnnals of Oncology
    Volume30
    Issue number7
    DOIs
    StatePublished - Jul 1 2019

    Fingerprint

    Microsatellite Instability
    Tumor Burden
    Colorectal Neoplasms
    Disease-Free Survival
    Biomarkers
    Prospective Studies
    Mutation
    Population

    Keywords

    • checkpoint inhibitor
    • colorectal cancer (CRC)
    • immunotherapy
    • microsatellite instability (MSI)
    • tumor mutational burden (TMB)

    ASJC Scopus subject areas

    • Hematology
    • Oncology

    Cite this

    Schrock, A. B., Ouyang, C., Sandhu, J., Sokol, E., Jin, D., Ross, J. S., ... Fakih, M. (2019). Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Annals of Oncology, 30(7), 1096-1103. [mdz134]. https://doi.org/10.1093/annonc/mdz134

    Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. / Schrock, A. B.; Ouyang, C.; Sandhu, J.; Sokol, E.; Jin, D.; Ross, J. S.; Miller, V. A.; Lim, D.; Amanam, I.; Chao, J.; Catenacci, D.; Cho, M.; Braiteh, F.; Klempner, S. J.; Ali, S. M.; Fakih, M.

    In: Annals of Oncology, Vol. 30, No. 7, mdz134, 01.07.2019, p. 1096-1103.

    Research output: Contribution to journalArticle

    Schrock, AB, Ouyang, C, Sandhu, J, Sokol, E, Jin, D, Ross, JS, Miller, VA, Lim, D, Amanam, I, Chao, J, Catenacci, D, Cho, M, Braiteh, F, Klempner, SJ, Ali, SM & Fakih, M 2019, 'Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer', Annals of Oncology, vol. 30, no. 7, mdz134, pp. 1096-1103. https://doi.org/10.1093/annonc/mdz134
    Schrock, A. B. ; Ouyang, C. ; Sandhu, J. ; Sokol, E. ; Jin, D. ; Ross, J. S. ; Miller, V. A. ; Lim, D. ; Amanam, I. ; Chao, J. ; Catenacci, D. ; Cho, M. ; Braiteh, F. ; Klempner, S. J. ; Ali, S. M. ; Fakih, M. / Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. In: Annals of Oncology. 2019 ; Vol. 30, No. 7. pp. 1096-1103.
    @article{34dd724f155a45878377e50e4c651ff1,
    title = "Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer",
    abstract = "Background: Microsatellite instability (MSI) is a biomarker for response to immune checkpoint inhibitors (ICPIs). PD-1 inhibitors in metastatic colorectal carcinoma (mCRC) with MSI-high (MSI-H) have demonstrated a high disease control rate and favorable progression-free survival (PFS); however, reported response rates to pembrolizumab and nivolumab are variable and often <50{\%}, suggesting that additional predictive biomarkers are needed. Methods: Clinicopathologic data were collected from patients with MSI-H mCRC confirmed by hybrid capture-based next-generation sequencing (NGS) treated with PD-1/L1 inhibitors at five institutes. Tumor mutational burden (TMB) was determined on 0.8-1.1 Mb of sequenced DNA and reported as mutations/Mb. Potential biomarkers of response and time to progression were analyzed by univariate and multivariate analyses. Once TMB was confirmed as a predictive biomarker, a larger dataset of 18 140 unique CRC patients was analyzed to define the relevance of the identified TMB cut-point. Results: A total of 22 patients were treated with PD-1/L1 inhibitors including 19 with pembrolizumab monotherapy. Among tested variables, TMB showed the strongest association with objective response (OR; P < 0.001) and PFS, by univariate (P < 0.001) and multivariate analysis (P < 0.01). Using log-rank statistics, the optimal predictive cut-point for TMB was estimated between 37 and 41 mutations/Mb. All 13 TMBhigh cases responded, while 6/9 TMBlow cases had progressive disease. The median PFS for TMBhigh has not been reached (median follow-up >18 months) while the median PFS for TMBlow was 2 months. A TMB of 37.4 mutations/Mb in a large MSI-H mCRC population (821/18, 140 cases; 4.5{\%}) evaluated by NGS corresponded to the 35th percentile cut-point. Conclusions: TMB appears to be an important independent biomarker within MSI-H mCRC to stratify patients for likelihood of response to ICPIs. If validated in prospective studies, TMB may play an important role in guiding the sequencing and/or combinations of ICPIs in MSI-H mCRC.",
    keywords = "checkpoint inhibitor, colorectal cancer (CRC), immunotherapy, microsatellite instability (MSI), tumor mutational burden (TMB)",
    author = "Schrock, {A. B.} and C. Ouyang and J. Sandhu and E. Sokol and D. Jin and Ross, {J. S.} and Miller, {V. A.} and D. Lim and I. Amanam and J. Chao and D. Catenacci and M. Cho and F. Braiteh and Klempner, {S. J.} and Ali, {S. M.} and M. Fakih",
    year = "2019",
    month = "7",
    day = "1",
    doi = "10.1093/annonc/mdz134",
    language = "English (US)",
    volume = "30",
    pages = "1096--1103",
    journal = "Annals of Oncology",
    issn = "0923-7534",
    publisher = "Oxford University Press",
    number = "7",

    }

    TY - JOUR

    T1 - Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer

    AU - Schrock, A. B.

    AU - Ouyang, C.

    AU - Sandhu, J.

    AU - Sokol, E.

    AU - Jin, D.

    AU - Ross, J. S.

    AU - Miller, V. A.

    AU - Lim, D.

    AU - Amanam, I.

    AU - Chao, J.

    AU - Catenacci, D.

    AU - Cho, M.

    AU - Braiteh, F.

    AU - Klempner, S. J.

    AU - Ali, S. M.

    AU - Fakih, M.

    PY - 2019/7/1

    Y1 - 2019/7/1

    N2 - Background: Microsatellite instability (MSI) is a biomarker for response to immune checkpoint inhibitors (ICPIs). PD-1 inhibitors in metastatic colorectal carcinoma (mCRC) with MSI-high (MSI-H) have demonstrated a high disease control rate and favorable progression-free survival (PFS); however, reported response rates to pembrolizumab and nivolumab are variable and often <50%, suggesting that additional predictive biomarkers are needed. Methods: Clinicopathologic data were collected from patients with MSI-H mCRC confirmed by hybrid capture-based next-generation sequencing (NGS) treated with PD-1/L1 inhibitors at five institutes. Tumor mutational burden (TMB) was determined on 0.8-1.1 Mb of sequenced DNA and reported as mutations/Mb. Potential biomarkers of response and time to progression were analyzed by univariate and multivariate analyses. Once TMB was confirmed as a predictive biomarker, a larger dataset of 18 140 unique CRC patients was analyzed to define the relevance of the identified TMB cut-point. Results: A total of 22 patients were treated with PD-1/L1 inhibitors including 19 with pembrolizumab monotherapy. Among tested variables, TMB showed the strongest association with objective response (OR; P < 0.001) and PFS, by univariate (P < 0.001) and multivariate analysis (P < 0.01). Using log-rank statistics, the optimal predictive cut-point for TMB was estimated between 37 and 41 mutations/Mb. All 13 TMBhigh cases responded, while 6/9 TMBlow cases had progressive disease. The median PFS for TMBhigh has not been reached (median follow-up >18 months) while the median PFS for TMBlow was 2 months. A TMB of 37.4 mutations/Mb in a large MSI-H mCRC population (821/18, 140 cases; 4.5%) evaluated by NGS corresponded to the 35th percentile cut-point. Conclusions: TMB appears to be an important independent biomarker within MSI-H mCRC to stratify patients for likelihood of response to ICPIs. If validated in prospective studies, TMB may play an important role in guiding the sequencing and/or combinations of ICPIs in MSI-H mCRC.

    AB - Background: Microsatellite instability (MSI) is a biomarker for response to immune checkpoint inhibitors (ICPIs). PD-1 inhibitors in metastatic colorectal carcinoma (mCRC) with MSI-high (MSI-H) have demonstrated a high disease control rate and favorable progression-free survival (PFS); however, reported response rates to pembrolizumab and nivolumab are variable and often <50%, suggesting that additional predictive biomarkers are needed. Methods: Clinicopathologic data were collected from patients with MSI-H mCRC confirmed by hybrid capture-based next-generation sequencing (NGS) treated with PD-1/L1 inhibitors at five institutes. Tumor mutational burden (TMB) was determined on 0.8-1.1 Mb of sequenced DNA and reported as mutations/Mb. Potential biomarkers of response and time to progression were analyzed by univariate and multivariate analyses. Once TMB was confirmed as a predictive biomarker, a larger dataset of 18 140 unique CRC patients was analyzed to define the relevance of the identified TMB cut-point. Results: A total of 22 patients were treated with PD-1/L1 inhibitors including 19 with pembrolizumab monotherapy. Among tested variables, TMB showed the strongest association with objective response (OR; P < 0.001) and PFS, by univariate (P < 0.001) and multivariate analysis (P < 0.01). Using log-rank statistics, the optimal predictive cut-point for TMB was estimated between 37 and 41 mutations/Mb. All 13 TMBhigh cases responded, while 6/9 TMBlow cases had progressive disease. The median PFS for TMBhigh has not been reached (median follow-up >18 months) while the median PFS for TMBlow was 2 months. A TMB of 37.4 mutations/Mb in a large MSI-H mCRC population (821/18, 140 cases; 4.5%) evaluated by NGS corresponded to the 35th percentile cut-point. Conclusions: TMB appears to be an important independent biomarker within MSI-H mCRC to stratify patients for likelihood of response to ICPIs. If validated in prospective studies, TMB may play an important role in guiding the sequencing and/or combinations of ICPIs in MSI-H mCRC.

    KW - checkpoint inhibitor

    KW - colorectal cancer (CRC)

    KW - immunotherapy

    KW - microsatellite instability (MSI)

    KW - tumor mutational burden (TMB)

    UR - http://www.scopus.com/inward/record.url?scp=85071187366&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85071187366&partnerID=8YFLogxK

    U2 - 10.1093/annonc/mdz134

    DO - 10.1093/annonc/mdz134

    M3 - Article

    C2 - 31038663

    AN - SCOPUS:85071187366

    VL - 30

    SP - 1096

    EP - 1103

    JO - Annals of Oncology

    JF - Annals of Oncology

    SN - 0923-7534

    IS - 7

    M1 - mdz134

    ER -